FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 339:578-583 August 27, 1998 Number 9 Next

	Full Text PDF Editorial by Adamson, J. W. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Several studies have suggested that if recombinant human erythropoietin (epoetin) is administered subcutaneously rather than intravenously, a lower dose may be sufficient to maintain the hematocrit at a given level.

Methods In a randomized, unblinded trial conducted at 24 hemodialysis units at Veterans Affairs medical centers, we assigned 208 patients who were receiving long-term hemodialysis and epoetin therapy to treatment with either subcutaneous or intravenous epoetin. The dose was initially reduced until the hematocrit was below 30 percent and then was gradually increased to a level that would maintain the hematocrit in the range of 30 to 33 percent for 26 weeks. We compared the average doses in the 26-week maintenance phase and the discomfort associated with the two routes of administration.

Results For the 107 patients treated by the subcutaneous route, the average weekly dose of epoetin during the maintenance phase was 32 percent less than that for the 101 patients treated by the intravenous route (mean [±SD], 95.1±75.0 vs. 140.3±88.5 U per kilogram of body weight per week; P<0.001). Only one patient in the subcutaneous-therapy group withdrew from the study because of pain at the injection site, and 86 percent rated the pain associated with subcutaneous administration as ranging from absent to mild.

Conclusions In patients receiving hemodialysis, subcutaneous administration of epoetin can maintain the hematocrit in a desired target range, with an average weekly dose of epoetin that is lower than with intravenous administration.

Source Information

From the Boston Veterans Affairs Medical Center and Department of Medicine, Boston University School of Medicine, Boston (J.S.K.); the Veterans Affairs Cooperative Studies Program Coordinating Center, Hines, Ill. (D.J.R., W.G.H.); the Veterans Affairs Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, Albuquerque, N.M. (C.L.F.); New York Veterans Affairs Medical Center and the Department of Medicine, New York University School of Medicine, New York (D.S.G.); Milwaukee Veterans Affairs Medical Center and the Department of Medicine, Medical College of Wisconsin, Milwaukee (J.G.K.); and Miami Veterans Affairs Medical Center and the Department of Medicine, University of Miami School of Medicine, Miami (C.A.V.).

Address reprint requests to Dr. Kaufman at the Renal Section (111-RE), Boston Veterans Affairs Medical Center, 150 S. Huntington Ave., Boston, MA 02130.

Full Text of this Article

This article has been cited by other articles:

• Macdougall, I. C., Rossert, J., Casadevall, N., Stead, R. B., Duliege, A.-M., Froissart, M., Eckardt, K.-U. (2009). A Peptide-Based Erythropoietin-Receptor Agonist for Pure Red-Cell Aplasia. NEJM 361: 1848-1855 [Abstract] [Full Text]  
• Bacchus, S., O'Mara, N., Manley, H., Fishbane, S. (2009). Meeting New Challenges in the Management of Anemia of Chronic Kidney Disease Through Collaborative Care with Pharmacists. The Annals of Pharmacotherapy 43: 1857-1866 [Abstract] [Full Text]  
• Bonafont, X., Bock, A., Carter, D., Brunkhorst, R., Carrera, F., Iskedjian, M., Molemans, B., Dehmel, B., Robbins, S. (2009). A meta-analysis of the relative doses of erythropoiesis-stimulating agents in patients undergoing dialysis. NDT Plus 2: 347-353 [Abstract] [Full Text]  
• Macdougall, I. C. (2009). Biosimilar epoetins. Nephrol Dial Transplant 24: 1698-1699 [Full Text]  
• Fang, Y.-W., Chang, C.-H. (2009). SUBCUTANEOUS ADMINISTRATION OF DARBEPOETIN ALFA EFFECTIVELY MAINTAINS HEMOGLOBIN CONCENTRATIONS AT EXTENDED DOSE INTERVALS IN PERITONEAL DIALYSIS PATIENTS. pdi 29: 199-203 [Abstract] [Full Text]  
• Carrera, F., Burnier, M. (2009). Use of darbepoetin alfa in the treatment of anaemia of chronic kidney disease: clinical and pharmacoeconomic considerations. NDT Plus 2: i9-i17 [Abstract] [Full Text]  
• Bommer, J., Asmus, G., Wenning, M., Bommer, G. (2008). A comparison of haemoglobin levels and doses in haemodialysis patients treated with subcutaneous or intravenous darbepoetin alfa: a German prospective, randomized, multicentre study. Nephrol Dial Transplant 23: 4002-4008 [Abstract] [Full Text]  
• Lee, Y. K., Kim, S. G., Seo, J. W., Oh, J. E., Yoon, J.-W., Koo, J.-R., Kim, H. J., Noh, J. W. (2008). A comparison between once-weekly and twice- or thrice-weekly subcutaneous injection of epoetin alfa: results from a randomized controlled multicentre study. Nephrol Dial Transplant 23: 3240-3246 [Abstract] [Full Text]  
• West, R. M., Harris, K., Gilthorpe, M. S., Tolman, C., Will, E. J. (2007). Functional Data Analysis Applied to a Randomized Controlled Clinical Trial in Hemodialysis Patients Describes the Variability of Patient Responses in the Control of Renal Anemia. J. Am. Soc. Nephrol. 18: 2371-2376 [Abstract] [Full Text]  
• Coyne, D. W. (2007). Practice Recommendations Based on Low, Very Low, and Missing Evidence. CJASN 2: 11-12 [Full Text]  
• Lucas, C., Carrera, F., Jorge, C., Boquinhas, H., Pais, M. J. (2006). Effectiveness of weekly darbepoetin alfa in the treatment of anaemia of HIV-infected haemodialysis patients. Nephrol Dial Transplant 21: 3202-3206 [Abstract] [Full Text]  
• Messa, P., Nicolini, M. A., Cesana, B., Brezzi, B., Zattera, T., Magnasco, A., Moroni, G., Campise, M. (2006). Efficacy prospective study of different frequencies of Epo administration by i.v. and s.c. routes in renal replacement therapy patients. Nephrol Dial Transplant 21: 431-436 [Abstract] [Full Text]  
• Moist, L. M, Muirhead, N., Wazny, L. D, Gallo, K. L, Heidenheim, A P., House, A. A (2006). Erythropoietin Dose Requirements When Converting from Subcutaneous to Intravenous Administration Among Patients on Hemodialysis. The Annals of Pharmacotherapy 40: 198-203 [Abstract] [Full Text]  
• Bennett, C. L., Cournoyer, D., Carson, K. R., Rossert, J., Luminari, S., Evens, A. M., Locatelli, F., Belknap, S. M., McKoy, J. M., Lyons, E. A., Kim, B., Sharma, R., Costello, S., Toffelmire, E. B., Wells, G. A., Messner, H. A., Yarnold, P. R., Trifilio, S. M., Raisch, D. W., Kuzel, T. M., Nissenson, A., Lim, L.-C., Tallman, M. S., Casadevall, N. (2005). Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. Blood 106: 3343-3347 [Abstract] [Full Text]  
• Galliford, J. W., Malasana, R., Farrington, K. (2005). Switching from subcutaneous to intravenous erythropoietin {alpha} in haemodialysis patients requires a major dose increase. Nephrol Dial Transplant 20: 1956-1962 [Abstract] [Full Text]  
• Vercaigne, L. M., Collins, D. M., Penner, S. B. (2005). Conversion From Subcutaneous to Intravenous Erythropoietin in a Hemodialysis Population. J Clin Pharmacol 45: 895-900 [Abstract] [Full Text]  
• Justice, G., Kessler, J. F., Jadeja, J., Campos, L., Weick, J., Chen, C.-F., Heatherington, A. C., Amado, R. G. (2005). A randomized, multicenter study of subcutaneous and intravenous darbepoetin alfa for the treatment of chemotherapy-induced anemia. Ann Oncol 16: 1192-1198 [Abstract] [Full Text]  
• Grzeszczak, W., Sulowicz, W., Rutkowski, B., de Vecchi, A. F., Scanziani, R., Durand, P.-Y., Bajo, A., Vargemezis, V., on behalf of the European Collaborative Group, (2005). The efficacy and safety of once-weekly and once-fortnightly subcutaneous epoetin {beta} in peritoneal dialysis patients with chronic renal anaemia. Nephrol Dial Transplant 20: 936-944 [Abstract] [Full Text]  
• Bennett, C. L., Luminari, S., Nissenson, A. R., Tallman, M. S., Klinge, S. A., McWilliams, N., McKoy, J. M., Kim, B., Lyons, E. A., Trifilio, S. M., Raisch, D. W., Evens, A. M., Kuzel, T. M., Schumock, G. T., Belknap, S. M., Locatelli, F., Rossert, J., Casadevall, N. (2004). Pure Red-Cell Aplasia and Epoetin Therapy. NEJM 351: 1403-1408 [Abstract] [Full Text]  
• Ramakrishnan, R., Cheung, W. K., Wacholtz, M. C., Minton, N., Jusko, W. J. (2004). Pharmacokinetic and Pharmacodynamic Modeling of Recombinant Human Erythropoietin After Single and Multiple Doses in Healthy Volunteers. J Clin Pharmacol 44: 991-1002 [Abstract] [Full Text]  
• Henry, D. H., Bowers, P., Romano, M. T., Provenzano, R. (2004). Epoetin Alfa: Clinical Evolution of a Pleiotropic Cytokine. Arch Intern Med 164: 262-276 [Abstract] [Full Text]  
• Rossert, J., Casadevall, N., Eckardt, K.-U. (2004). Anti-Erythropoietin Antibodies and Pure Red Cell Aplasia. J. Am. Soc. Nephrol. 15: 398-406 [Full Text]  
• Snyder, J. J., Foley, R. N., Gilbertson, D. T., Vonesh, E. F., Collins, A. J. (2004). Hemoglobin Levels and Erythropoietin Doses in Hemodialysis and Peritoneal Dialysis Patients in the United States. J. Am. Soc. Nephrol. 15: 174-179 [Abstract] [Full Text]  
• Locatelli, F., Canaud, B., Giacardy, F., Martin-Malo, A., Baker, N., Wilson, J. (2003). Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo). Nephrol Dial Transplant 18: 362-369 [Abstract] [Full Text]  
• Reddan, D. N., Frankenfield, D. L., Klassen, P. S., Coladonato, J. A., Szczech, L., Johnson, C. A., Besarab, A., Rocco, M., McClellan, W., Wish, J., Owen, W. F. Jr (2003). Regional variability in anaemia management and haemoglobin in the US. Nephrol Dial Transplant 18: 147-152 [Abstract] [Full Text]  
• Fisher, J. W. (2003). Erythropoietin: Physiology and Pharmacology Update. Exp. Biol. Med. 228: 1-14 [Abstract] [Full Text]  
• Rizzo, J. D., Lichtin, A. E., Woolf, S. H., Seidenfeld, J., Bennett, C. L., Cella, D., Djulbegovic, B., Goode, M. J., Jakubowski, A. A., Lee, S. J., Miller, C. B., Rarick, M. U., Regan, D. H., Browman, G. P., Gordon, M. S. (2002). Use of Epoetin in Patients With Cancer: Evidence-Based Clinical Practice Guidelines of the American Society of Clinical Oncology and the American Society of Hematology. JCO 20: 4083-4107 [Abstract] [Full Text]  
• Rizzo, J. D., Lichtin, A. E., Woolf, S. H., Seidenfeld, J., Bennett, C. L., Cella, D., Djulbegovic, B., Goode, M. J., Jakubowski, A. A., Lee, S. J., Miller, C. B., Rarick, M. U., Regan, D. H., Browman, G. P., Gordon, M. S. (2002). Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 100: 2303-2320 [Abstract] [Full Text]  
• Coladonato, J. A., Frankenfield, D. L., Reddan, D. N., Klassen, P. S., Szczech, L. A., Johnson, C. A., Owen, W. F. Jr. (2002). Trends in Anemia Management among US Hemodialysis Patients. J. Am. Soc. Nephrol. 13: 1288-1295 [Abstract] [Full Text]  
• Weiss, L. G., Clyne, N., Fihlho, J. D., Frisenette-Fich, C., Kurkus, J., Svensson, B. (2000). The efficacy of once weekly compared with two or three times weekly subcutaneous epoetin {beta}: results from a randomized controlled multicentre trial. Nephrol Dial Transplant 15: 2014-2019 [Abstract] [Full Text]  
• Chapel, S. H., Veng-Pedersen, P., Schmidt, R. L., Widness, J. A. (2000). A Pharmacodynamic Analysis of Erythropoietin-Stimulated Reticulocyte Response in Phlebotomized Sheep. J. Pharmacol. Exp. Ther. 295: 346-351 [Abstract] [Full Text]  
• Goodnough, L. T., Skikne, B., Brugnara, C. (2000). Erythropoietin, iron, and erythropoiesis. Blood 96: 823-833 [Abstract] [Full Text]  
• MORENO, F., SANZ-GUAJARDO, D., LOPEZ-GOMEZ, J. M., JOFRE, R., VALDERRABANO, F. (2000). Increasing the Hematocrit Has a Beneficial Effect on Quality of Life and Is Safe in Selected Hemodialysis Patients. J. Am. Soc. Nephrol. 11: 335-342 [Abstract] [Full Text]  
• Kizer, K. W. (1999). The "New VA": A National Laboratory for Health Care Quality Management. American Journal of Medical Quality 14: 3-20 [Abstract]  
• (1998). IV vs. SQ Epoetin for Hemodialysis Patients. JWatch General 1998: 5-5 [Full Text]  
• Adamson, J. W., Eschbach, J. W. (1998). Erythropoietin for End-Stage Renal Disease. NEJM 339: 625-627 [Full Text]